Roth Capital Expects Stronger Earnings for Nuvectis Pharma

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Investment analysts at Roth Capital increased their FY2028 earnings estimates for shares of Nuvectis Pharma in a research note issued to investors on Tuesday, August 12th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of $2.46 for the year, up from their previous forecast of $2.43. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.01) per share.

Nuvectis Pharma (NASDAQ:NVCT) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.05).

NVCT has been the subject of a number of other reports. HC Wainwright reduced their price target on shares of Nuvectis Pharma from $15.00 to $10.00 and set a “buy” rating for the company in a research report on Monday, August 4th. Wall Street Zen lowered shares of Nuvectis Pharma from a “hold” rating to a “sell” rating in a research report on Sunday, June 29th.

Nuvectis Pharma Price Performance

NVCT opened at $6.37 on Wednesday. The company has a fifty day moving average price of $7.75 and a 200-day moving average price of $8.24. The firm has a market capitalization of $162.18 million, a P/E ratio of -5.44 and a beta of -0.26. Nuvectis Pharma has a one year low of $4.44 and a one year high of $11.80.

Hedge Funds Weigh In On Nuvectis Pharma

Several hedge funds and other institutional investors have recently modified their holdings of the company. Baldwin Wealth Partners LLC MA increased its position in shares of Nuvectis Pharma by 0.7% during the first quarter. Baldwin Wealth Partners LLC MA now owns 358,461 shares of the company’s stock valued at $3,502,000 after buying an additional 2,500 shares during the period. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Nuvectis Pharma during the second quarter valued at approximately $28,000. JPMorgan Chase & Co. lifted its position in Nuvectis Pharma by 3,398.9% during the second quarter. JPMorgan Chase & Co. now owns 6,263 shares of the company’s stock valued at $47,000 after purchasing an additional 6,084 shares during the period. Cubist Systematic Strategies LLC bought a new position in Nuvectis Pharma during the fourth quarter valued at approximately $34,000. Finally, Blue Zone Wealth Advisors LLC bought a new position in Nuvectis Pharma during the first quarter valued at approximately $102,000. 96.77% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Nuvectis Pharma news, major shareholder Marlio Charles Mosseri purchased 5,603 shares of the stock in a transaction on Friday, June 20th. The stock was acquired at an average cost of $7.99 per share, with a total value of $44,767.97. Following the completion of the purchase, the insider directly owned 2,981,806 shares of the company’s stock, valued at approximately $23,824,629.94. This trade represents a 0.19% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have acquired 39,045 shares of company stock valued at $314,300 over the last ninety days. Insiders own 30.52% of the company’s stock.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.